Device safety and effectiveness in the pediatric population: a US FDA perspective

Joy Samuels-Reid1, Judith U Cope, Audrey E Morrison

  • 1Division of Anesthesiology, General Hospital, Infection Control and Dental Devices, Center for Devices and Radiological Health, Office of Device Evaluation, FDA, Rockville, MD 20857, USA. joy.samuels-reid@fda.hhs.gov

Insights

Ensuring safe pediatric medical device use requires educating healthcare providers and manufacturers about unique risks. Heightened awareness of differing adverse events and risk mitigation strategies is crucial for child safety.

Area of Science:

  • Pediatric medical device safety and regulation
  • Healthcare quality improvement
  • Adverse event monitoring in pediatrics

Background:

  • The U.S. Food and Drug Administration (FDA) acknowledges significant challenges in the safe and responsible use of medical devices in children.
  • Effective education for manufacturers and healthcare providers is essential for addressing pediatric-specific medical device issues.
  • Adverse events and risk mitigation strategies for medical devices can differ significantly between adult and pediatric populations, including within pediatric subpopulations.

Purpose of the Study:

  • To highlight the importance of education for manufacturers and healthcare providers regarding pediatric medical device safety.
  • To emphasize the unique challenges and considerations for medical device use in the pediatric population.
  • To underscore the need for recognizing and addressing differences in adverse events and risk mitigation for pediatric subpopulations.

Main Methods:

  • Review of FDA perspectives on pediatric medical device challenges.
  • Analysis of the role of education in medical device safety.
  • Discussion of the differences in adverse events and risk mitigation between adult and pediatric populations.

Main Results:

  • Medical device safety in children faces unique hurdles.
  • Education is a critical component for safe pediatric device use.
  • Adverse events and risk mitigation strategies vary across pediatric groups.

Conclusions:

  • Manufacturers and healthcare providers must be aware of pediatric-specific medical device issues.
  • Recognizing differing adverse events and risk mitigation is key to reducing harm.
  • Increased awareness promotes the safe and effective use of medical devices in children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...